Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

Rashmi Kanagal-Shamanna, Sanam Loghavi, Courtney D. DiNardo, L. Jeffrey Medeiros, Guillermo Garcia-Manero, Elias Jabbour, Mark J. Routbort, Rajyalakshmi Luthra, Carlos E. Bueso-Ramos and Joseph D. Khoury

1Department of Hematopathology and 2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

ABSTRACT

A subset of patients with familial platelet disorder with propensity to myeloid malignancy and germline RUNX1 mutation develops hematological malignancies, often myelodysplastic syndrome/acute myeloid leukemia, currently recognized in the 2016 WHO classification. Patients who develop hematologic malignancies are typically young, respond poorly to conventional therapy, and need allogeneic stem cell transplant from non-familial donors. Understanding the spectrum of bone marrow morphologic and genetic findings in these patients is critical to ensure diagnostic accuracy and develop criteria to recognize the onset of hematologic malignancies, particularly myelodysplastic syndrome. However, bone marrow features remain poorly characterized. To address this knowledge gap, we analyzed the clinicopathologic and genetic findings of 11 patients from 7 pedigrees. Of these, 6 patients did not develop hematologic malignancies over a 22-month follow-up period; 5 patients developed hematologic malignancies (3 acute myeloid leukemia; 2 myelodysplastic syndrome). All patients had thrombocytopenia at initial presentation. All 6 patients who did not develop hematologic malignancies showed baseline bone marrow abnormalities: low-for-age cellularity (n=4), dysmegakaryopoiesis (n=5), megakaryocytic hypoplasia/hyperplasia (n=5), and eosinophilia (n=4). Two patients had multiple immunophenotypic alterations in CD34-positive myeloblasts; 1 patient had clonal hematopoiesis. In contrast, patients who developed hematologic malignancies had additional cytopenia(s) (n=4), abnormal platelet granulation (n=5), bone marrow hypercellularity (n=4), dysplasia in ≥2 lineages including megakaryocytes (n=3) and acquired clonal genetic aberrations (n=5). In conclusion, our study demonstrated that specific bone marrow abnormalities and acquired genetic alterations may be harbingers of progression to hematological malignancies in patients with familial platelet disorder with germline RUNX1 mutation.

Introduction

The widespread use of next-generation sequencing (NGS)-based assays has facilitated an increased recognition of familial clustering of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Familial syndromes in which MDS/AML is a primary feature include familial platelet disorder with predisposition to myeloid malignancy (FPDMM) associated with germline RUNX1 mutations, GATA2-associated syndromes, familial AML with CEBPA mutation, and syndromes associated with germline mutations in SRP72, ANKRD26, DDX41, or ETV6. Accordingly, the 2016
revision to the WHO classification system for myeloid neoplasms has incorporated a section on “myeloid neoplasms with germline predisposition”.4

FPDMM (OMIM #601399) is an autosomal-dominant disorder with variable penetrance genetically defined by the presence of germline RUNX1 mutation. RUNX1 encodes one of the α subunits of a core-binding transcription factor and plays a critical role in hematopoiesis.

### Table 1A. Clinical, laboratory and peripheral blood findings on FPDMM patients.

<table>
<thead>
<tr>
<th>Pedigree</th>
<th>Age/sex</th>
<th>Family history</th>
<th>Diagnosis</th>
<th>Follow up</th>
<th>WBC</th>
<th>Hgb</th>
<th>MCV</th>
<th>PC</th>
<th>MPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>A II-3</td>
<td>46/M</td>
<td>+</td>
<td>FPDMM**+</td>
<td>A&amp;W, 29 months</td>
<td>6.3</td>
<td>12.9</td>
<td>99</td>
<td>119</td>
<td>12.3</td>
</tr>
<tr>
<td>A III-1</td>
<td>7/F</td>
<td>+</td>
<td>FPDMM**+</td>
<td>A&amp;W, 27 months; 23 months post stem cell transplant</td>
<td>3.9</td>
<td>9.7</td>
<td>103</td>
<td>63</td>
<td>10.1</td>
</tr>
<tr>
<td>B II-1</td>
<td>53/F</td>
<td>+</td>
<td>FPDMM**+</td>
<td>Died; 56.1 months from HM diagnosis</td>
<td>4.9</td>
<td>9.3</td>
<td>83</td>
<td>20</td>
<td>9.1</td>
</tr>
<tr>
<td>C II-1</td>
<td>48/F</td>
<td>+</td>
<td>FPDMM**+</td>
<td>Died, 54 months from HM diagnosis</td>
<td>3.2</td>
<td>11</td>
<td>100</td>
<td>69</td>
<td>9.3</td>
</tr>
<tr>
<td>C II-3</td>
<td>42/M</td>
<td>+</td>
<td>FPDMM**+</td>
<td>Died, 8 months from HM diagnosis</td>
<td>4</td>
<td>13</td>
<td>103</td>
<td>33</td>
<td>NA</td>
</tr>
<tr>
<td>A III-2</td>
<td>4/F</td>
<td>+</td>
<td>FPDMM**+</td>
<td>A&amp;W, 25 months</td>
<td>6.8</td>
<td>12.5</td>
<td>86</td>
<td>122</td>
<td>8.7</td>
</tr>
<tr>
<td>C I-1</td>
<td>70/F</td>
<td>+</td>
<td>FPDMM**+</td>
<td>A&amp;W, 8 months</td>
<td>5.5</td>
<td>13.1</td>
<td>95</td>
<td>134</td>
<td>9.9</td>
</tr>
<tr>
<td>D I-1</td>
<td>57/F</td>
<td>+</td>
<td>FPDMM**+</td>
<td>A&amp;W, 39 months</td>
<td>6.5</td>
<td>14</td>
<td>89</td>
<td>92</td>
<td>9.5</td>
</tr>
<tr>
<td>E II-1</td>
<td>38/M</td>
<td>+</td>
<td>FPDMM**+</td>
<td>Lost for follow up</td>
<td>3.2</td>
<td>14.1</td>
<td>93</td>
<td>77</td>
<td>9.6</td>
</tr>
<tr>
<td>F I-1</td>
<td>27/M</td>
<td>+</td>
<td>FPDMM**+</td>
<td>A&amp;W, 15 months</td>
<td>4.5</td>
<td>14.4</td>
<td>93</td>
<td>99</td>
<td>7.2</td>
</tr>
<tr>
<td>G I-1</td>
<td>57/M</td>
<td>+</td>
<td>FPDMM**+</td>
<td>A&amp;W, 22 months</td>
<td>5.9</td>
<td>13.1</td>
<td>88</td>
<td>88</td>
<td>NA</td>
</tr>
</tbody>
</table>

WBC: white blood cell count; Hgb: hemoglobin; MCV: mean corpuscular volume; PC: platelet count; MPV: mean platelet volume. Cytopenia(s) defined by laboratory reference range (matched for age). A&W: alive and well; AML MRC: acute myeloid leukemia with myelodysplasia-related changes; FPDMM**+: FPDMM with hematological malignancy; FPDMM**: FPDMM without hematological malignancy; MDS-MLD: myelodysplastic syndrome with multilineage dysplasia; MDS-EB-1: myelodysplastic syndrome with excess blasts-1; HM: hematological malignancies; ND: not done; NA: not available; SM: systemic mastocytosis.

### Table 1B. Bone marrow morphologic and flow cytometry immunophenotypic findings on the FPDMM patients.

<table>
<thead>
<tr>
<th>Pedigree</th>
<th># of BM specimens</th>
<th>Age-matched cellularity</th>
<th>Megakaryocyte number</th>
<th>Megakaryocyte dysplasia</th>
<th>Granulocytic dysplasia</th>
<th>Erythroid dysplasia</th>
<th>Ring sideroblasts (%)</th>
<th>CD34+ blasts (%)</th>
<th>Lymphoid aggregates</th>
<th>CD13</th>
<th>CD33</th>
<th>CD34</th>
<th>CD38</th>
<th>CD117</th>
<th>CD123</th>
<th>CD47</th>
<th>Hemagones</th>
</tr>
</thead>
<tbody>
<tr>
<td>A II-3</td>
<td>7</td>
<td>↑ ↑</td>
<td>+ - + + - - - 2</td>
<td>1.00</td>
<td>↓ + + ↓ + ↑ +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A III-1</td>
<td>8</td>
<td>↓ ↓</td>
<td>too too too too too</td>
<td>2.76</td>
<td>↑ + ↑ ↓ ↑ +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B II-1</td>
<td>11</td>
<td>↑ ↓</td>
<td>too too too too too</td>
<td>83.00</td>
<td>↑ + + ↑ + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C II-1</td>
<td>5</td>
<td>↑ ↓</td>
<td>too too too too too</td>
<td>93.00</td>
<td>+ + + + + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C II-3</td>
<td>5</td>
<td>↑ ↓</td>
<td>too too too too too</td>
<td>91.00</td>
<td>+ + + + + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A III-2</td>
<td>4</td>
<td>↓ ↓</td>
<td>+ - + + - - - &lt;1</td>
<td>0.80</td>
<td>+ + + + + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C I-1</td>
<td>2</td>
<td>↑ ↑</td>
<td>+ - + + + + +</td>
<td>0.08</td>
<td>+ + + + + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D I-1</td>
<td>5</td>
<td>Adequate</td>
<td>↑ + + + + + +</td>
<td>0.60</td>
<td>+ + + + + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E II-1</td>
<td>1</td>
<td>↓ ↓</td>
<td>+ - + + + + +</td>
<td>0.50</td>
<td>+ + + + + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F I-1</td>
<td>1</td>
<td>↑ ↓</td>
<td>too too too too too</td>
<td>ND ND ND ND ND ND ND ND ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G I-1</td>
<td>1</td>
<td>↓ ↑</td>
<td>+ - + - + - - - - 0</td>
<td>0.70</td>
<td>+ + + + + +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Suboptimal quality bone marrow (insufficient number of megakaryocytes available for evaluation). Dysplasia defined as dysmorphic forms >10% of the megakaryocytes. ND: not done; BM: bone marrow
myeloid differentiation and platelet function. FPDMM is characterized by abnormalities in platelet number and/or function, namely defective release of δ granules, and a propensity to develop early-onset MDS/AML or, rarely, T-lymphoblastic leukemia/lymphoma. Until now, about 50 pedigrees with germline RUNX1 mutations have been reported. A subset (median, 35%; range: 22-60%) of FPDMM patients undergoes transformation to hematological malignancies (HM), usually MDS or AML (FPDMMHM+), associated with the acquisition of additional somatic genetic lesions. FPDMMHM+ respond poorly to conventional therapy and require unique management strategies such as allogeneic stem cell transplant (in all pediatric patients and in eligible adult patients during remission), genetic counseling and work-up and identification of family members with germline RUNX1 mutation. In this setting, allogeneic stem cell transplant is generally from unrelated donors who need to be carefully screened for germline mutations. Close surveillance and prompt recognition of FPDMMHM+ facilitate

Table 2. FPDMM pedigrees with cytogenetic results and somatic mutation analysis using a combination of next-generation based sequencing and conventional techniques.

<table>
<thead>
<tr>
<th>Pedigree</th>
<th>Diagnosis</th>
<th>Genetic testing for germline</th>
<th>Somatic mutations*</th>
<th>Cyto genetic studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>A II-3</td>
<td>FPDMMHM+, MDS-MLD</td>
<td>c.582A&gt;G p.K194N</td>
<td>6</td>
<td>None</td>
</tr>
<tr>
<td>A III-1</td>
<td>FPDMMHM+, MDS-EB-1</td>
<td>c.582A&gt;G p.K194N</td>
<td>6</td>
<td>None</td>
</tr>
<tr>
<td>B II-1</td>
<td>FPDMMHM+, AML MRC</td>
<td>c.719delC p.Pro240Hisfs (probably benign)</td>
<td>7</td>
<td>NM_001754.4 (RUNX1): c.582A&gt;G p.K194N</td>
</tr>
<tr>
<td>C II-1</td>
<td>FPDMMHM+, AML MRC, SM</td>
<td>Partial gene deletion (at least exons 1-6)</td>
<td>I through 6</td>
<td>NM_001754.4 (RUNX1): c.582A&gt;G p.K194N</td>
</tr>
<tr>
<td>C II-3</td>
<td>FPDMMHM+, AML MRC</td>
<td>Partial gene deletion (at least exons 1-6)</td>
<td>I through 6</td>
<td>None</td>
</tr>
<tr>
<td>A III-2</td>
<td>FPDMMHM-</td>
<td>c.582A&gt;G p.K194N</td>
<td>6</td>
<td>None</td>
</tr>
<tr>
<td>C I-1</td>
<td>FPDMMHM-</td>
<td>Partial gene deletion (at least exons 1-6)</td>
<td>I through 6</td>
<td>NM_001754.4 (RUNX1): c.582A&gt;G p.K194N</td>
</tr>
<tr>
<td>D I-1</td>
<td>FPDMMHM-</td>
<td>c.890C&gt;A p.W297*</td>
<td>8</td>
<td>None</td>
</tr>
<tr>
<td>E II-1</td>
<td>FPDMMHM+</td>
<td>c.496C&gt;T p.R166*</td>
<td>5</td>
<td>ND</td>
</tr>
<tr>
<td>F I-1</td>
<td>FPDMMHM+</td>
<td>c.308dup p.T104fs</td>
<td>4</td>
<td>ND</td>
</tr>
<tr>
<td>G I-1</td>
<td>FPDMMHM+</td>
<td>c.1098_1103dupCGGCAT p.I366_G367dup</td>
<td>9</td>
<td>None</td>
</tr>
</tbody>
</table>

*NGS-based somatic gene mutation analysis using 28-gene myeloid panel, FLT3-ITD and CEBPA. NGS: next-generation sequencing; FPDMM: familial platelet disorder with predisposition to myeloid malignancy; FISH: fluorescence in situ hybridization; AML MRC: acute myeloid leukemia with myelodysplasia-related changes; FPDMMHM+: FPDMM with hematological malignancy; FPDMMHM-: FPDMM without hematological malignancy; MDS-MLD: myelodysplastic syndrome with multilineage dysplasia; MDS-EB-1: myelodysplastic syndrome with excess blasts-1; ND: not done; SM: systemic mastocytosis; VAF: variant allele frequency.
tates planning and timely therapeutic interventions before or at the time of leukemic transformation.

The diagnosis of MDS in FPDMM is particularly challenging. Few reports have described dysplastic changes in megakaryocytes due to the underlying germline \textit{RUNX1} mutation in asymptomatic FPDMM patients.\textsuperscript{6,20,21} Additionally, the frequency of clonal hematopoiesis in asymptomatic FPDMM patients below 50 years of age is significantly higher (~67%) compared to that of the healthy general population.\textsuperscript{2,22} Currently, there are no criteria or guidelines available in the literature for diagnosis, evaluation and monitoring for HM in these patients.\textsuperscript{4} On the other hand, due to the aggressive therapeutic interventions implicated by the diagnosis of a HM, diagnostic accuracy and avoidance of overcalling MDS is of critical importance. Thus, there is a need to determine the pathologic features associated with FPDMM and progression to MDS. To begin addressing these gaps in knowledge, a thorough understanding of the bone marrow (BM) features in FPDMM patients and the characteristics associated with progression to HM is required. It is our understanding that no other study has addressed this issue in a systematic manner and this much needed knowledge base is currently lacking for pathologists and the rest of the clinical diagnostic team who are required to diagnose and evaluate patients with FDPMM associated with \textit{RUNX1} mutation.

In the study herein, we performed a systematic evaluation of BM morphologic, cytogenetic and molecular findings in 11 patients from 7 distinct FPDMM pedigrees at various stages of disease evolution. We show that baseline BM morphologic and immunophenotypic abnormalities are present in asymptomatic FPDMM patients without MDS/AML. Awareness of these changes is important in order to exert caution in establishing a diagnosis of MDS, an actionable event in this context. We also compared the clinical, morphologic, cytogenetic, immunophenotypic and genetic findings between patients with FPDMMHM- and FPDMM HM+ who had been followed with serial BM examinations over a median interval of 27 months. We identified specific pathologic features and we propose criteria that can facilitate the recognition of MDS in this setting for timely therapeutic interventions. These findings also highlight the need for baseline and serial BM examination with multimodal ancillary testing to monitor for development of MDS/AML.

### Methods

#### Study Group

We selected pedigrees of FPDMM with germline \textit{RUNX1} mutations that were evaluated at our institution. In some cases, the proband (defined here as the first diagnosed family member) was evaluated at an outside hospital or clinic, whereas other members were referred to our institution following the proband’s diagnosis. This study was approved by the Institutional Review Board and informed consent was obtained from all patients in accordance with the Declaration of Helsinki.

#### Histopathologic Evaluation

Hematoxylin-eosin stained BM core biopsy and/or clot specimens and Wright-Giemsa-stained peripheral blood (PB) and BM aspirate smears and/or touch imprints at baseline and various time points were assessed using standard criteria.\textsuperscript{23,24} Cytopenia(s) were defined based on institutional laboratory reference ranges. For enumeration of megakaryocytes, we considered 2-6 megakaryocytes per high-power field as a criterion for normal range. Prussian blue staining was used for quantifying ring sideroblasts. In selected cases, immunohistochemistry studies for CD34 and CD61 were performed using standard techniques on automated stainers (Leica Biosystems, Buffalo Grove, IL, USA) using antibodies against CD34 (MY10, 1:40; BD Biosciences, Franklin Lakes, NJ, USA) and CD61 (2F2, 1:100; Cell Marque, Rocklin, CA, USA). The morphologic findings were independently reviewed by 2 independent hematopathologists (RK-S and JDK).

#### Multiparameter Flow Cytometry Analysis

Flow cytometry (FC) immunophenotypic analysis was performed on BM aspirates as described previously.\textsuperscript{25,26} Aberrancies in expression levels of CD13, CD33, CD34, CD38, CD117, CD123 and additional markers were assessed on CD34+/CD10-/CD19- myeloid precursors and hematogones were quantified.

**Figure 1.** Representative image showing the location of the various types of exonic \textit{RUNX1} mutations in this study group.
Abnormalities in myelomonocytic maturation were assessed as previously described.26

**Karyotyping and Fluorescence in situ Hybridization**

Conventional G-band karyotype analysis and fluorescence in situ hybridization (FISH) on selected cases were performed using standard methods described previously.27,28 All results were reported according to the 2013 International System for Human Cytogenetic Nomenclature.29

**Gene Mutation Analysis**

For germline RUNX1 variant detection, we used genomic DNA extracted from disease-free whole blood/BM samples (in FPDMM<sup>26</sup>) or cultured skin fibroblasts (in FPDMM<sup>26</sup>). For all pedigrees except C, RUNX1 mutation was assessed by polymerase chain reaction (PCR) amplification followed by direct sequencing. NM_001754.3 was used as the reference sequence for the RUNX1 gene for alignment. For pedigree C, amplicon-based exome sequencing targeted the ANKRD26, CEBPA, DDX41, ETV6, FLI1, GATA2, RUNX1, SRP72, and TP53 genes using the illumina system. The deletion was confirmed by exon-level oligo comparative genomic hybridization. Clinical interpretation was performed per published guidelines.30

For assessment of somatic mutations, amplicon-based NGS-based analysis using a clinically-validated 28-gene myeloid panel was performed on genomic DNA extracted from BM on a MiSeq sequencer (Illumina, San Diego, CA, USA) as described previously.31,32 FLT3 internal tandem duplications and CEBPA mutations were assessed by well-established alternative methods.31

**Results**

**Clinical characteristics**

Our study cohort included 11 patients with FPDMM with germline RUNX1 mutations from 7 unique pedigrees, labeled A through G. There were 6 females and 5 males with a median age of 42 years (range: 4-70) who were tested in various clinical settings and at different stages of clinical progression. The median age at time of diagnosis of MDS/AML in FPDMM<sup>26</sup> patients was 45 years (range: 7-53). The patients were either asymptomatic or had a long-standing propensity for bleeding that was often misdiagnosed as immune thrombocytopenic purpura. Upon evaluation, all patients had mild to moderate thrombocytopenia. The median platelet count was 88 x 10<sup>9</sup>/L (range: 20-134). The clinical characteristics are presented in Table 1. Six of 7 pedigrees had a family history of thrombocytopenia or leukemia; 1 patient had “sporadic” thrombocytopenia, however, details regarding the family history on the pater-

![Figure 2. Representative images from the BM biopsy/aspirate smears of the asymptomatic FPDMM patients from various pedigrees.](image)
nal side were not available for this latter patient. The reasons for germline $RUNX1$ mutation testing included: evaluation for early-onset MDS, an extensive family history of MDS/AML, FPDMM diagnosis in a relative, and confirmation of a suspected germline mutation identified by NGS-based multi-gene somatic mutation profiling for thrombocytopenia in a patient with no known family history of bleeding or leukemia. The pedigree, diagnosis and genetic alterations, to various extents, in 4 of the 7 pedigrees have been reported previously.18 The detailed pedigrees for each of the families are provided in the Online Supplementary Figures S1 and S2.

Characteristics of germline $RUNX1$ mutations

The types of germline $RUNX1$ alterations observed in this study cohort included substitutions (1 missense, 2 nonsense), duplications (n=2) and deletions (n=2). The deletion in pedigree C was large and spanned exons 1 through 6. Four of the 7 $RUNX1$ germline alterations involved the Runt1 homology domain (RHD); 3 involved the transactivation domain (TAD). Two cases that transformed to AML had additional somatic $RUNX1$ mutations, both of which involved the Runt domain. The location and type of germline alterations identified in each of the pedigrees are depicted in Figure 1. Five of the detected $RUNX1$ mutations have not been reported previously.

PB, BM histologic, immunophenotypic, cytogenetic and molecular findings

Within our study group, 6 of 11 patients with FPDMM had no evidence of MDS/AML (FPDMM$^{\text{nos}}$), and 5 patients developed AML or MDS (FPDMM$^{\text{nos}+}$) over the follow-up time period. The 5 FPDMM$^{\text{nos}+}$ patients included FPDMM with AML (n=5), and FPDMM with MDS (n=2). All 11 patients underwent BM examination; 7 patients (including 3 of 6 FPDMM$^{\text{nos}+}$ patients) had BM evaluations performed at multiple time points.

PB findings

All 6 FPDMM$^{\text{nos}}$ patients had stable thrombocytopenia (median, 96 x 10^3 /μL, range: 77-134); 1 patient also had mild leukopenia (no decreased absolute neutrophil count) and no patients had anemia. Mean corpuscular volume (MCV) was within normal range in all patients. Absolute eosinophilia was noted in 3 out of 6 patients. PB smears showed normal sized platelets in all but 1 patient who had normal sized platelets with few large forms that were adequately granulated. In contrast, the median platelet count of FPDMM$^{\text{nos}+}$ patients was lower at 63 (range: 20-119). Contrary to FPDMM$^{\text{nos}}$, all patients with FPDMM$^{\text{nos}+}$ had 1 or more cytopenia(s) in addition to thrombocytopenia (anemia in 4 and leukopenia in 2 patients). In 1 patient, the platelet count decreased further at the time of development of MDS. Macrocytosis was present in 4 out of 5 patients. Absolute eosinophilia was noted in 1 out of 5 patients. PB smears showed platelets with anisocytosis and abnormalities in granulation (hypogranulation and agranulation). Two out of 4 patients showed dysplastic neutrophils that included cytoplasmic hypogranulation and abnormal nuclear segmentation.

BM histologic findings

BM from all 6 FPDMM$^{\text{nos}}$ patients showed baseline morphologic abnormalities. Age-matched BM cellularity was decreased in 4 patients, increased in 1 patient and adequate in 1 patient. Morphologic abnormalities were most apparent in the megakaryocytic lineage. The number of megakaryocytes was increased in 5 patients, decreased in 2 patients and could not be assessed in 1 patient. Megakaryocytes were dysmorphic, often small with scant cytoplasm and nuclear hypolobation, with asynchronous nuclear cytoplasmic maturation; the dysmorphic forms accounted for more than 10% of the megakaryocytes in 5 patients, barring 1 case in which megakaryocytic dysplasia could not be evaluated due to the poor quality of the specimen. In 1 case megakaryocytic dysplasia was associated with granulocytic dysplasia; however, a diagnosis of MDS was not established because the patient did not have unexplained cytopenia(s) other than mild and stable thrombocytopenia. None of the other patients showed dysplasia in the granulocytic or erythroid lineages. BM eosinophilia was present in 4 out of 6 patients. None of the patients had fibrosis. BM findings in representative FPDMM cases within pedigrees are presented in Figures 2 and 3.

BM samples from 4 out of 5 FPDMM$^{\text{nos}+}$ patients showed increased BM cellularity for age compared to FPDMM$^{\text{nos}+}$ patients (80% versus 17%, P=0.08, Fisher’s exact test). The megakaryocytes were adequate in number in 1 patient, and decreased in 4 patients. Three patients had sufficient precursor cells for adequate morphologic evaluation. All patients had dysmegakaryopoiesis with dysplasia in an additional lineage (dyserythropoiesis and/or dysgranulopoiesis). Two FPDMM/AML patients had too few cells to assess for dysplasia due to the presence of many blasts. BM eosinophilia was present in 2 out of 5 patients. None of the 5 patients had BM fibrosis. The diagnoses on FPDMM$^{\text{nos}+}$
patients included: MDS with excess blasts (EB)-1 (n=1), MDS with multilinage dysplasia (n=1), and AML with myelodysplasia-related changes (MRC; n=3). AML-MRC was attributable to a history of MDS in 1 patient, morphologic dysplasia in >50% of precursors in at least 2 lineages in a second patient and del(7q) abnormality in a third patient; this patient also developed systemic mastocytosis during remission.

**Immunophenotypic findings**

The immunophenotype of CD34-positive myeloid blasts was analyzed by FC immunophenotyping in 5 FPDMMHM+ patients. CD34-positive myeloblasts showed immunophenotypic abnormalities similar to those observed in MDS or a stem cell neoplasm. These included CD13 increased (1/5), CD38 decreased (3/5), CD117 increased (1/5), and CD123 increased (3/5). Hematogones were absent in 2 cases. In 2 out of 5 FPDMMHM patients, multiple FC aberrations which are typical of MDS or a stem cell neoplasm were noted.

The immunophenotypic findings in the FPDMMHM+ patients showed aberrancies consistent with the diagnosis. The PB and BM findings are summarized in Table 1.

**Somatic clonal cytogenetic and molecular aberrations**

Karyotypic data were available for all patients and NGS mutation data were available for 9 out of 11 patients. None of the 6 FPDMMHM+ patients had karyotypic abnormalities. Two out of 6 patients showed inv(9) chromosomal polymorphism. One out of 4 FPDMMHM+ patients who underwent NGS testing showed a somatic DNMT3A splice site mutation (allele frequency 14.1%). In the absence of cytopenia or hematologic malignancy, this finding was consistent with clonal hematopoiesis of indeterminate potential [pedigree C 1-1].

In contrast, all 5 FPDMMHM- patients who had acquired clonal cytogenetic abnormalities and/or somatic gene mutation(s) in addition to germline RUNX1 mutation (4 with karyotype abnormality; 2 with somatic mutations and both of these cases also had a second RUNX1 mutation). These results are summarized in Table 2.

**Clinical course and outcome**

Follow-up data were available for 10 out of 11 patients (Table 1). The median follow-up duration was 27.4 months (range: 8-56.1). The median follow up for FPDMMHM+ patients was 22.3 months. Five FPDMMHM+ patients with available follow-up data are alive without development of hematological malignancy. All 3 FPDMMHM+ patients with AML (B II-1, C II-1 and C II-3) died. The FPDMMHM+ patient with MDS-EB-1 (A III-1) underwent allogeneic stem cell transplant and is alive and well. The FPDMMHM+ patient (A II-3) who developed MDS with multilineage dysplasia is awaiting therapy with hypomethylating agents.

Using serial BM examinations and comparing certain specific parameters to the baseline BM, 1 patient progressed to overt MDS over a 29-month follow-up period. This asymptomatic patient (A II-3) was evaluated solely due to the diagnosis of FPDMMHM+ in the offspring. The platelet count was minimally decreased and perhaps present life-long, and attributable to germline RUNX1 mutation. Mild anemia (Hgb, 12.9 g/dL) was noted at presentation, but the significance and duration were not clear. The initial baseline BM showed ~10% dysmorphic megakaryocytes without granulocytic or erythroid dysplasia. FC immunophenotypic findings showed aberrant CD34 positive myeloblasts with decreased CD13 and CD38 expression and increased CD123 expression (Table 1). Conventional cytogenetic studies showed a low-level del(11)(q13q23) in 2 out of 50 metaphases, confirmed to involve KMT2A/MLL deletion by FISH in 9.5% of interphase nuclei. At this time, although del(11q) is an MDS-defining abnormality, due to the low-level of the del(11q) clone, in the absence of dysplasia in other lineage(s) other than megakaryocytes, and unclear etiology of anemia, a diagnosis of MDS was not made but a concern was raised. Therefore, the patient was monitored closely with BM exams every 6 months. Over a 23-month follow-up interval, the patient presented anemic and thrombocytopenic, and del(11q) persisted at a low level (1-2 of 20 metaphases). At the 29-month follow up, BM showed additional dysplasia involving the erythroid lineage that coincided with expansion of the del(11q) clone to 8 out of 20 metaphases. At this time, the patient was diagnosed with MDS. At last follow up, he was scheduled to start treatment with hypomethylating agents.

**Discussion**

We describe the spectrum of BM pathologic findings in 11 patients belonging to 7 unique FPDMM pedigrees identified in various clinical settings and at different stages of clinical progression. The findings in this study highlight the importance of initial and serial BM evaluation in FPDMM patients and underscore the need to establish specific criteria for the diagnosis of MDS in patients with a germline predisposition to MDS/AML.

Although few studies have described megakaryocytic abnormalities in BM aspirate smears, systematic analysis of BM morphologic, immunophenotypic, and genetic findings in FPDMM are rare. The other study by Tsang et al. reported serial BM specimens of patients with various etiologies of congenital thrombocytopenia, including a case of FPDMM. The authors describe 3 morphologic patterns at initial presentation: (1) cases with myelodysplastic/ myeloproliferative features such as hypercellularity, myeloid predominance and numerous micromegakaryocytes, (2) cases with hypocellular marrow and small megakaryocytes, as noted in the case with FPDMM, paralleling the observations in our series, and (3) cases with normal morphology. Similar to the findings in our study group, disease progression in their series was also associated with the development of additional dysplasia in the erythroid and myeloid lineages as well as cytogenetic abnormalities.

In the study herein we show that FPDMM is characterized by baseline morphologic abnormalities that include low-for-age BM cellularity and dysplastic megakaryopoeisis in the absence of MDS/AML. A subset of these FPDMM+ patients also showed immunophenotypic aberrancies in CD34-positive myeloid blasts diagnostic of a stem cell neoplasm. However, these patients lacked unexplained cytopenia(s) other than thrombocytopenia, and have been followed up over a median of 22.3 months without development of MDS/AML. Awareness of these baseline BM abnormalities in FPDMM patients is important for diagnosticians not to overlook MDS in FPDMM patients. This is not simply an academic issue; the diagnosis of MDS in FPDMM patients has considerable treatment implications. MDS and AML arising in the context of FDPMM respond poorly to conventional therapy; therefore, aggressive interventions including allogeneic stem cell transplant from non-familial...
donors is required.

FPDMM patients showed an unusually high proportion of dysmorphic megakaryocytes which were small in size with scant basophilic cytoplasm and hypolobated nuclei. These abnormalities corroborate the results of published in vitro studies showing the critical role of RUNX1 in terminal differentiation of megakaryocytes and the impact of RUNX1 mutations on megakaryopoiesis. Bluteau et al. demonstrated, in vitro, morphologic abnormalities in megakaryocytes derived from CD34+ hematopoietic progenitors of FPDMM patients. These abnormalities were related to a block in maturation, manifested as small megakaryocytes with a high nucleus/cytoplasm ratio, and decreased ploidy or nuclear lobation. Dysmegakaryopoiesis in the BM of FPDMM patients similar to those observed in our study have been described in a few reports. Bluteau et al. also demonstrated a 60-80% decrease in the total number of megakaryocytes derived from CD34+ hematopoietic progenitors of FPDMM patients. In contrast, a substantial percentage of patients showed increased numbers of megakaryocytes in the present case series. The variant findings may represent the phenotypic diversity of the various RUNX1 mutations.

Another interesting finding was PB and BM eosinophilia that were noted in 4 out of 6 FPDMM patients in the study herein. Eosinophilia is characteristic of AML with RUNX1 translocations, such as AML with RUNX1-RUNX1T1 or AML with RUNX1–CBFA2T3. However, it is unclear if eosinophilia in FPDMM is directly related to the RUNX1 mutation or secondary to another etiology. One FPDMM patient (C II-1) who progressed to AML subsequently developed systemic mastocytosis with KIT D816V mutation during remission, suggesting an alternative explanation for eosinophilia in this patient. There was no increase in mast cells in the other family members in this pedigree who underwent evaluation (C II-3 and C I-1).

The findings in the study herein illustrate the unique challenges associated with the diagnosis of MDS in patients with FPDMM and the need for developing specific criteria for establishing the diagnosis of MDS in these patients. However, at this time, there are no guidelines available for this purpose. By comparing the clinicopathologic features of FPDMM and FPDMM patients in this study, we found certain consistent findings in all FPDMM patients with MDS/AML. These findings included: (1) presence of anemia and/or leukopenia in addition to thrombocytopenia, (2) multilineage dysplasia, and (3) presence of an additional clonal (somatic) event, either a cytogenetic or a molecular aberration. Based on these findings, we propose the following criteria as a helpful guide for the diagnosis of MDS in FPDMM patients (Table 3). However, the series is small, and the proposed criteria need validation in additional studies. The criteria should be used with appropriate clinico-pathologic correlation. The decision to treat MDS is very challenging as it must be tailored to the individual and as such requires input from both oncologists and pathologists.

Figure 3. Representative images of the BM biopsy/aspirate smears of FPDMM patients with MDS. (A) 7-year old girl diagnosed with MDS (proband, III-1); BM biopsy is hypocellular for age; (B) BM aspirate smears show increased blasts (dashed arrows) and severe neutrophilic hypogranulation; (C) father’s (II-3) BM with frequent megakaryocytes that are small and hypolobated; (D) CD61 immunohistochemistry highlights dysmorphic megakaryocytes.
Other studies have shown that leukemic transformation in FPDMM is always associated with an additional clonal (somatic) event. Acquired cytogenetic aberrations include del(5q), +8, del(7q), del(11q23), trisomy 12, and t(2;11)(q31;p15), and reported somatic gene mutations include a second RUNX1 mutation, and mutations in ASXL1, IDH1, TET2, CEBPA and CDC25C. Mutations have not been confirmed by other studies. However, acquisition of clonal somatic aberrations is not pathognomonic of leukemic transformation and are often missed by clinical NGS-based analysis of these genes. NGS studies show abnormalities. We also recommend NGS mutation analysis for the workup of FPDMM patients with BM morphologic and FC immunophenotypic abnormalities capable of detecting deletions, duplications and rearrangements. Following initial BM evaluation after 6 months showed persistent dysplasia with stable thrombocytopenia and no evidence of MDS; however, the follow up on this patient is short (~8 months).

The findings of recurrent BM morphologic, immunophenotypic and genetic abnormalities underscore the importance of initial baseline and serial BM evaluation in FPDMM. Identification of specific BM abnormalities in FPDMM patients can provide measurable parameters to assess progressive changes during serial follow up for monitoring for potential development of MDS/AML, illustrated by patient II-3 in pedigree A. The role of precise diagnostic and monitoring criteria useful for establishing a diagnosis of MDS in these patients; the impact of making a diagnosis of MDS in FPDMM patients is underscored by the significant therapeutic implications including allogeneic stem cell transplantation. The role of precise diagnostic and monitoring criteria using a multimodal approach in the evaluation of patients with FPDMM cannot be overemphasized.

**Funding**

This work was partly supported by institutional startup funds awarded to R K-S, MD Anderson Cancer Center Leukemia SPORE CA 100632 and Charif Souki Cancer Research Fund.
References


